Aravive to Host Key Opinion Leader Symposium on May 11, 2022
05. Mai 2022 07:00 ET
|
Aravive, Inc.
HOUSTON, May 05, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that it...
Aravive Announces Poster Presentations at the 2022 ASCO Annual Meeting
29. April 2022 07:00 ET
|
Aravive, Inc.
HOUSTON, April 29, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the...
Aravive Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
01. April 2022 07:00 ET
|
Aravive, Inc.
HOUSTON, April 01, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced that it has...
Aravive Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates
31. März 2022 16:05 ET
|
Aravive, Inc.
Reported positive data from Phase 1b trials of batiraxcept in clear cell renal cell carcinoma and pancreatic adenocarcinoma in 1Q’22; on track to report updated data in 2Q’22Dosed first patient in...
Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
30. März 2022 08:00 ET
|
Aravive, Inc.
HOUSTON, March 30, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced today that it...
Aravive Appoints Scott Dove, Ph.D., as Chief Operating Officer
22. März 2022 07:00 ET
|
Aravive, Inc.
HOUSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the...
Aravive to Participate In-Person at 34th Annual ROTH Conference
07. März 2022 07:00 ET
|
Aravive, Inc.
HOUSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced that Gail...
Aravive Announces Positive Updated Data and New Biomarker Data from Phase 1b Study of Batiraxcept in Clear Cell Renal Cell Carcinoma
03. März 2022 07:00 ET
|
Aravive, Inc.
46% Best Overall Response Rate in the ITT Population 63% Best Overall Response Rate in the sAXL/GAS6 Biomarker High Population 6-month Progression-Free Survival Rate in the ITT Population of 79%...
Aravive to Present Updated Modeling Data from Batiraxcept Clinical Trials at the AACR Annual Meeting
02. März 2022 07:00 ET
|
Aravive, Inc.
HOUSTON, March 02, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, will present updated...
Aravive Announces First Patient Dosed in Phase 2 Study of Batiraxcept in Clear Cell Renal Cell Carcinoma
31. Januar 2022 07:00 ET
|
Aravive, Inc.
HOUSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that the...